

# **Microbiome Therapeutics: Global Markets**

https://marketpublishers.com/r/MF0071075100EN.html

Date: January 2023

Pages: 175

Price: US\$ 2,500.00 (Single User License)

ID: MF0071075100EN

## **Abstracts**

### Report Scope:

BCC Research's new report, Microbiome Therapeutics: Global Markets, provides a comprehensive analysis of the microbiome therapeutics market in global context, including market forecasts and sales through 2027. The report analyzes the market by segmenting it into the various types of microbiome therapeutics, based on the strategies used for treatment: additive (fecal matter transplants or FMTs, live biotherapeutic products or LBPs), modulatory (postbiotics, prebiotics) and subtractive microbiome therapeutics (phages and antimicrobials). This study surveys the microbiome therapeutics market by application or disease segment: infectious diseases, metabolic diseases, cancer, gut-brain axis, and others. The market is assessed in the following geographic regions: North America, Europe, and emerging markets. Emerging markets include countries like India, China, Korea, Taiwan, Africa, Australia, New Zealand, Canada, and Latin America.

The report features leading clinical trials indicating the status and phase of development. New developments and patents are boosting growth of this market in the global context.

The new BCC report provides comprehensive profiles of market players in the industry. The industry structure chapter focuses on the changing market trends, market players and leading pipeline candidates. This chapter covers influential mergers and acquisitions and other collaborations or partnerships that happened during the evaluation period of this report.

Strengths, weaknesses, threats, and opportunities that are expected to play a role in the microbiome therapeutics market are evaluated in detail.



The markets for prebiotics and probiotics labeled as nutritional or dietary supplements are excluded from this report. Prebiotics and probiotics are included when used in the context of microbiome therapy.

### Report Includes:

32 data tables and 44 additional tables

An up-to-date overview and analysis of the global and regional markets for microbiome therapeutics

Analyses of the global market trends, with historic market revenue (sales data) for 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2027

Discussion of the industry growth driving factors and major technology challenges and issues affecting the market for microbiome therapeutics as a basis for projecting demand over the next few years (2022-2027)

Estimation of the actual market size and revenue forecast for global microbiome therapeutics market in USD million terms, and corresponding market share analysis by technology type, application, and region

Highlights of this innovation driven market covering current trends in genome sequencing industry, disease areas of application, clinical trials and their stages, and recent breakthrough innovations etc.

Assessment of the recent industry structure for microbiome therapeutics, ongoing research (R&D) activities, analysis of competitive environment, and the COVID-19 impact on the marketplace

Review of the patents and patent applications on microbiome therapeutics, and related scientific publications during the analysis period

Competitive landscape of this market featuring leading biopharmaceutical companies, their product portfolios, financial updates, and market share analysis based on recent segmental revenues

Profile description of the major market participants, including Assembly



Biosciences, Finch Therapeutics, Second Genome, Evelo Biosciences, Ysopia Bioscience and Evelo Biosciences



## **Contents**

#### **CHAPTER 1 INTRODUCTION**

- 1.1 Study Goals and Objectives
- 1.2 Reasons for Doing This Study
- 1.3 What's New in This Report?
- 1.4 Scope of Report
- 1.5 Information Sources
- 1.6 Methodology
- 1.7 Geographic Breakdown
- 1.8 Analyst's Credentials
- 1.9 BCC Custom Research
- 1.10 Related BCC Research Reports

#### **CHAPTER 2 SUMMARY AND HIGHLIGHTS**

2.1 Key Highlights

#### **CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND**

- 3.1 Benefits
- 3.2 The Human Microbiome
  - 3.2.1 Different Microbiomes in Humans
  - 3.2.2 Microbiome, Human Health and Disease
  - 3.2.3 Technologies Aiding Microbiome Research
  - 3.2.4 Microbiome Research Projects
- 3.3 Microbiome Therapeutics
  - 3.3.1 Strategies for the Development of Microbiome Therapeutics
  - 3.3.2 Microbiome Therapeutics Disease Areas
  - 3.3.3 Regulatory Landscape for Microbiome Therapeutics

## **CHAPTER 4 MARKET BREAKDOWN BY TYPE OF THERAPEUTIC**

- 4.1 Introduction
- 4.2 Market Overview
  - 4.2.1 Market Revenue
  - 4.2.2 Market Shares
- 4.3 Additive Microbiome Therapeutics



- 4.3.1 Fecal Microbiota Transplants (FMTs)
- 4.3.2 Live Biotherapeutic Products (LBPs)
- 4.3.3 Market Overview
- 4.3.4 Market Revenue
- 4.3.5 Market Shares
- 4.4 Modulatory Microbiome Therapeutics
  - 4.4.1 Mechanism of Action
  - 4.4.2 Current Status
  - 4.4.3 Market Overview
  - 4.4.4 Market Revenue
  - 4.4.5 Market Shares
- 4.5 Subtractive Microbiome Therapeutics
  - 4.5.1 Mechanism of Action
  - 4.5.2 Current Status
  - 4.5.3 Market Overview
  - 4.5.4 Market Revenue
  - 4.5.5 Market Shares

#### CHAPTER 5 MARKET BREAKDOWN BY APPLICATION

- 5.1 Introduction
  - 5.1.1 Market Revenue
  - 5.1.2 Market Shares
- 5.2 Infections
  - 5.2.1 Clostridium Difficile Infection (CDI)
  - 5.2.2 Urinary Tract Infection (UTI)
  - 5.2.3 COVID-19
  - 5.2.4 Market Overview
  - 5.2.5 Market Revenue
- 5.3 Gastrointestinal (GIT) Diseases
  - 5.3.1 Market Overview
  - 5.3.2 Market Revenue
- 5.4 Metabolic Diseases
  - 5.4.1 Market Overview
  - 5.4.2 Market Revenue
- 5.5 Cancer
  - 5.5.1 Market Overview
  - 5.5.2 Market Revenue
- 5.6 Gut-Brain Axis Diseases



- 5.6.1 Market Overview
- 5.6.2 Market Revenue
- 5.7 Other Diseases
  - 5.7.1 Market Overview
  - 5.7.2 Market Revenue
- 5.8 Regional Markets Globally
  - 5.8.1 Market Shares

#### **CHAPTER 6 INDUSTRY STRUCTURE**

- 6.1 Investment in Microbiome Therapeutics
  - 6.1.1 Public Funding Initiatives
  - 6.1.2 Private Funding Initiatives
- 6.2 Collaborations and Partnerships
- 6.3 Licensing and Manufacturing Agreements
- 6.4 Mergers and Acquisitions
- 6.5 Leading Market Players in the Market for Microbiome Therapeutics
  - 6.5.1 Leading Market Players in Market for Additive Microbiome Therapeutics
  - 6.5.2 Leading Market Players in the Market for Modulatory Microbiome Therapeutics
- 6.5.3 Leading Market Players in the Market for Subtractive Microbiome Therapeutics
- 6.6 BCC Research Select Insights from Industry Leaders

#### **CHAPTER 7 PATENT ANALYSIS**

- 7.1 Patent Analysis
  - 7.1.1 Patents by Year
  - 7.1.2 Patents by Type
  - 7.1.3 Patents by Type of Disease
  - 7.1.4 Patents by Company
  - 7.1.5 Patents by Country
  - 7.1.6 Patents by Assignee

### **CHAPTER 8 CLINICAL TRIALS**

- 8.1 Clinical Trials by Disease Category
  - 8.1.1 Distribution Shares of Clinical Trials
- 8.2 Clinical Trials by Type of Therapeutic
  - 8.2.1 Distribution Shares of Clinical Trials by Type of Therapeutic
- 8.3 Clinical Trials by Company



- 8.3.1 Distribution Shares of Clinical Trials by Company
- 8.3.2 Microbiome Therapeutics in Discovery and Preclinical Development
- 8.3.3 Microbiome Therapeutics in Phase 3 Clinical Trials

#### **CHAPTER 9 ANALYSIS OF MARKET OPPORTUNITIES**

- 9.1 SWOT Analysis
  - 9.1.1 Strengths of Market for Microbiome Therapeutics
  - 9.1.2 Challenges in the Market for Microbiome Therapeutics
  - 9.1.3 Opportunities in the Market for Microbiome Therapeutics
  - 9.1.4 Threats to the Market for Microbiome Therapeutics

#### **CHAPTER 10 COMPANY PROFILES**

**4D PHARMA** 

AO BIOME LLC

ASSEMBLY BIOSCIENCES INC.

ARMATA PHARMACEUTICALS

AZITRA INC.

**BIOMICA** 

**BIOMX** 

CHAIN BIOTECHNOLOGY LTD.

**ELIGO BIOSCIENCE SAS** 

**ENTEROME SA** 

**EVELO BIOSCIENCES** 

FINCH THERAPEUTICS GROUP INC.

INTRALYTIX INC.

MAAT PHARMA

OSEL INC.

PYLUM BIOSCIENCES INC.

QUORUM INNOVATIONS LLC

REBIOTIX INC. (A FERRING COMPANY)

SECOND GENOME

SENDA BIOSCIENCES INC.

SERES THERAPEUTICS INC.

SFA THERAPEUTICS INC.

**SYNLOGIC** 

THERIVA BIOLOGICS INC.

VEDANTA BIOSCIENCES INC.



YSOPIA BIOSCIENCE INC.

**CHAPTER 11 APPENDIX: ACRONYMS** 



## **List Of Tables**

#### LIST OF TABLES

Summary Table: Global Market for Microbiome Therapeutics, by Type of Disease,

Through 2027

Table 1: Technology for Microbiome Research

Table 2: Dysbiosis in Microbiome

Table 3: Leading Pharmaceutical/Microbiome Therapeutics Partnerships

Table 4: Global Market for Microbiome Therapeutics, by Type, Through 2027

Table 5: Global Market Shares of Microbiome Therapeutics, by Type, 2027

Table 6: LBPs in Microbiome Therapeutics

Table 7: Global Market for Additive Microbiome Therapeutics, by Type, Through 2027

Table 8: Global Market Shares of Additive Microbiome Therapeutics, by Type, 2027

Table 9: Modulatory Microbiome Therapeutics

Table 10: Global Market for Modulatory Microbiome Therapeutics, by Type, Through 2027

Table 11: Global Market Shares of Modulatory Microbiome Therapeutics, by Type, 2027

Table 12: Global Market for Subtractive Microbiome Therapeutics, by Type, Through 2027

Table 13: Global Market Shares of Subtractive Microbiome Therapeutics, by Type, 2027

Table 14: R&D Expenditures in Microbiome Therapeutics, by Company, 2017-2019

Table 15: Global Market for Microbiome Therapeutics, by Type of Disease, Through 2027

Table 16: Global Market Shares of Microbiome Therapeutics, by Type of Disease, 2027

Table 17: Microbiome Therapeutics for Infections

Table 18: Global Market for Microbiome Therapeutics for Infections, by Region, Through 2027

Table 19: Microbiome Therapeutics for GIT Diseases

Table 20: Global Market for Microbiome Therapeutics for GIT Diseases, by Region,

Through 2027

Table 21: Microbiome Therapeutics for Metabolic Diseases

Table 22: Global Market for Microbiome Therapeutics for Metabolic Diseases, by

Region, Through 2027

Table 23: Microbiome Therapeutics for Cancer

Table 24: Global Market for Microbiome Therapeutics for Cancer, by Region, Through 2027

Table 25: Microbiome Therapeutics for Gut-Brain Axis Diseases

Table 26: Global Market for Microbiome Therapeutics for Gut-Brain Axis Diseases, by



Region, Through 2027

Table 27: Microbiome Therapeutics for Other Diseases

Table 28: Global Market for Microbiome Therapeutics for Other Diseases, by Region,

Through 2027

Table 29: Global Market for Microbiome Therapeutics, by Region, Through 2027

Table 30: Global Market Shares of Microbiome Therapeutics, by Region, 2027

Table 31: Historical Funding Activity, Microbiome Therapeutics, 2015 and 2016

Table 32: Public Funding, Microbiome Therapeutics, 2018-2022

Table 33: Venture Funding, Microbiome Therapeutics, 2017-Aug. 2020

Table 34: Collaborations and Partnerships in the Market for Microbiome Therapeutics, 2017-2022

Table 35: Licensing and Manufacturing Agreements in the Market for Microbiome Therapeutics, 2017-Aug. 2020

Table 36: Leading Developers of Additive Microbiome Therapeutics, 2022

Table 37: Leading Developers of Modulatory Microbiome Therapeutics, 2022

Table 38: Leading Developers of Subtractive Microbiome Therapeutics, 2022

Table 39: Patents Issued on Microbiome Therapeutics, by Year, 2017–2022

Table 40: Patents Issued on Microbiome Therapeutics, by Type, 2017–2022

Table 41: Patents Issued on Microbiome Therapeutics, by Type of Disease, 2017–2022

Table 42: Patents Issued on Microbiome Therapeutics, by Company, 2017–2022

Table 43: Patents Issued on Microbiome Therapeutics, by Country, 2017–2022

Table 44: Patents Issued on Microbiome Therapeutics, by Assignee, 2017–Aug. 2020

Table 45: Distribution of Clinical Trials on Microbiome Therapeutics, by Type of

Disease, 2022

Table 46: Distribution Shares of Clinical Trials on Microbiome Therapeutics, by Type of Disease, 2022

Table 47: Distribution Shares of Clinical Trials on Microbiome Therapeutics, by Type of Therapeutic

Table 48: Distribution Shares of Clinical Trials on Microbiome Therapeutics, by Type of Therapeutic

Table 49: Distribution Shares of Clinical Trials on Microbiome Therapeutics, by Company

Table 50: Distribution Shares of Clinical Trials on Microbiome Therapeutics for the Top 10 Companies

Table 51: Microbiome Therapeutics, Discovery and Preclinical Development

Table 52: Microbiome Therapeutics in Phase 3 Clinical Trials

Table 53: 4D Pharma: Pipeline

Table 54: AO Biome: Pipeline

Table 55: Assembly Biosciences: Pipeline



Table 56: Armata Pharmaceuticals: Pipeline

Table 57: Azitra: Pipeline

Table 58: Biomica: Pipeline

Table 59: BiomX: Pipeline

Table 60: Enterome: Pipeline

Table 61: Evelo Biosciences: Pipeline

Table 62: Finch Therapeutics: Pipeline

Table 63: Intralytix: Pipeline

Table 64: MaaT Pharma: Pipeline

Table 65: Osel: Pipeline

Table 66: Quorum Innovations: Pipeline

Table 67: Rebiotix: Pipeline

Table 68: Second Genome: Pipeline

Table 69: Seres Therapeutics: Pipeline

Table 70: SFA Therapeutics: Pipeline

Table 71: Synlogic: Pipeline

Table 72: Theriva Biologics: Pipeline

Table 73: Vedanta Biosciences: Pipeline

Table 74: Ysopia Bioscience: Pipeline

Table 75: Acronyms Used in This Report



## **List Of Figures**

#### LIST OF FIGURES

Summary Figure: Global Market for Microbiome Therapeutics, by Type of Disease, 2021-2027

- Figure 1: Differences between the Human Genome and the Microbiome
- Figure 2: Bacterial Distribution, by Body Site
- Figure 3: Essential Functions, Human Microbiome
- Figure 4: Dysbiosis and Human Health
- Figure 5: Summary of NIH Funding for Microbiome Research, 2012-2016
- Figure 6: Global Market for Microbiome Therapeutics, by Type, 2021-2027
- Figure 7: Global Market Shares of Microbiome Therapeutics, by Type, 2027
- Figure 8: Global Market for Additive Microbiome Therapeutics, by Type, 2021-2027
- Figure 9: Global Market Shares of Additive Microbiome Therapeutics, by Type, 2027
- Figure 10: Global Market for Modulatory Microbiome Therapeutics, by Type, 2021-2027
- Figure 11: Global Market Shares of Modulatory Microbiome Therapeutics, by Type, 2027
- Figure 12: Global Market for Subtractive Microbiome Therapeutics, by Type, 2021-2027
- Figure 13: Global Market Shares of Subtractive Microbiome Therapeutics, by Type, 2027
- Figure 14: Global Market for Microbiome Therapeutics, by Type of Disease, 2021-2027
- Figure 15: Global Market Shares of Microbiome Therapeutics, by Type of Disease, 2027
- Figure 16: Global Market for Microbiome Therapeutics for Infections, by Region, 2021-2027
- Figure 17: Global Market for Microbiome Therapeutics for GIT Diseases, by Region, 2021-2027
- Figure 18: Global Market for Microbiome Therapeutics for Metabolic Diseases, by Region, 2021-2027
- Figure 19: Global Market for Microbiome Therapeutics for Cancer, by Region, 2021-2027
- Figure 20: Global Market for Microbiome Therapeutics for Gut-Brain Axis Diseases, by Region, 2021-2027
- Figure 21: Global Market for Microbiome Therapeutics for Other Diseases, by Region, 2021-2027
- Figure 22: Global Market for Microbiome Therapeutics, by Region, 2021-2027
- Figure 23: Global Market Shares of Microbiome Therapeutics, by Region, 2027
- Figure 24: Patents Issued on Microbiome Therapeutics, by Year, 2017-2022
- Figure 25: Patents Issued on Microbiome Therapeutics, by Type, 2017-2022



- Figure 26: Patents Issued on Microbiome Therapeutics, by Type of Disease, 2017–2022
- Figure 27: Patents Issued on Microbiome Therapeutics, by Company, 2017-2022
- Figure 28: Patents Issued on Microbiome Therapeutics, by Country, 2017–2022
- Figure 29: Patents Issued on Microbiome Therapeutics, by Assignee, 2017–Aug. 2020
- Figure 30: Distribution Shares of Clinical Trials on Microbiome Therapeutics, by Type of Disease, 2022
- Figure 31: Distribution Shares of Clinical Trials on Microbiome Therapeutics by Type of Therapeutic
- Figure 32: Distribution Shares of Clinical Trials on Microbiome Therapeutics for the Top 10 Companies
- Figure 33: SWOT Analysis of the Market for Microbiome Therapeutics



## I would like to order

Product name: Microbiome Therapeutics: Global Markets

Product link: <a href="https://marketpublishers.com/r/MF0071075100EN.html">https://marketpublishers.com/r/MF0071075100EN.html</a>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

## **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/MF0071075100EN.html">https://marketpublishers.com/r/MF0071075100EN.html</a>